Literature DB >> 24812431

IKKε is key to induction of insulin resistance in the hypothalamus, and its inhibition reverses obesity.

Laís Weissmann1, Paula G F Quaresma1, Andressa C Santos1, Alexandre H B de Matos1, Vínicius D'Ávila Bittencourt Pascoal1, Tamires M Zanotto1, Gisele Castro1, Dioze Guadagnini1, Joelcimar Martins da Silva2, Licio A Velloso1, Jackson C Bittencourt2, Iscia Lopes-Cendes1, Mario J A Saad1, Patricia O Prada3.   

Abstract

IKK epsilon (IKKε) is induced by the activation of nuclear factor-κB (NF-κB). Whole-body IKKε knockout mice on a high-fat diet (HFD) were protected from insulin resistance and showed altered energy balance. We demonstrate that IKKε is expressed in neurons and is upregulated in the hypothalamus of obese mice, contributing to insulin and leptin resistance. Blocking IKKε in the hypothalamus of obese mice with CAYMAN10576 or small interfering RNA decreased NF-κB activation in this tissue, relieving the inflammatory environment. Inhibition of IKKε activity, but not TBK1, reduced IRS-1(Ser307) phosphorylation and insulin and leptin resistance by an improvement of the IR/IRS-1/Akt and JAK2/STAT3 pathways in the hypothalamus. These improvements were independent of body weight and food intake. Increased insulin and leptin action/signaling in the hypothalamus may contribute to a decrease in adiposity and hypophagia and an enhancement of energy expenditure accompanied by lower NPY and increased POMC mRNA levels. Improvement of hypothalamic insulin action decreases fasting glycemia, glycemia after pyruvate injection, and PEPCK protein expression in the liver of HFD-fed and db/db mice, suggesting a reduction in hepatic glucose production. We suggest that IKKε may be a key inflammatory mediator in the hypothalamus of obese mice, and its hypothalamic inhibition improves energy and glucose metabolism.
© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24812431     DOI: 10.2337/db13-1817

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  17 in total

Review 1.  Leptin signalling pathways in hypothalamic neurons.

Authors:  Obin Kwon; Ki Woo Kim; Min-Seon Kim
Journal:  Cell Mol Life Sci       Date:  2016-01-19       Impact factor: 9.261

Review 2.  Fat sensing and metabolic syndrome.

Authors:  Jang H Youn
Journal:  Rev Endocr Metab Disord       Date:  2014-12       Impact factor: 6.514

3.  Cdc2-like kinase 2 in the hypothalamus is necessary to maintain energy homeostasis.

Authors:  P G F Quaresma; L Weissmann; T M Zanotto; A C Santos; A H B de Matos; I C Furigo; F M Simabuco; J Donato; J C Bittencourt; I Lopes-Cendes; P O Prada
Journal:  Int J Obes (Lond)       Date:  2016-10-13       Impact factor: 5.095

Review 4.  Obesity-related cognitive impairment: The role of endothelial dysfunction.

Authors:  Joy Jones Buie; Luke S Watson; Crystal J Smith; Catrina Sims-Robinson
Journal:  Neurobiol Dis       Date:  2019-08-24       Impact factor: 5.996

Review 5.  Protein kinases: mechanisms and downstream targets in inflammation-mediated obesity and insulin resistance.

Authors:  Kalyana C Nandipati; Saravanan Subramanian; Devendra K Agrawal
Journal:  Mol Cell Biochem       Date:  2016-11-21       Impact factor: 3.396

Review 6.  Hypothalamic inflammation and gliosis in obesity.

Authors:  Mauricio D Dorfman; Joshua P Thaler
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-10       Impact factor: 3.243

Review 7.  Hypothalamic inflammation in metabolic disorders and aging.

Authors:  Anup Bhusal; Md Habibur Rahman; Kyoungho Suk
Journal:  Cell Mol Life Sci       Date:  2021-12-15       Impact factor: 9.261

8.  Hepatic IKKε expression is dispensable for high-fat feeding-induced increases in liver lipid content and alterations in glucose tolerance.

Authors:  J Jason Collier; Heidi M Batdorf; Tamra M Mendoza; David H Burk; Thomas M Martin; Jingying Zhang; Randall L Mynatt; Susan J Burke
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-10-29       Impact factor: 4.310

9.  FGF21 is required for the metabolic benefits of IKKε/TBK1 inhibition.

Authors:  Shannon M Reilly; Mohammad Abu-Odeh; Magdalene Ameka; Julia H DeLuca; Meghan C Naber; Benyamin Dadpey; Nima Ebadat; Andrew V Gomez; Xiaoling Peng; BreAnne Poirier; Elyse Walk; Matthew J Potthoff; Alan R Saltiel
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 14.808

Review 10.  Microglia activation due to obesity programs metabolic failure leading to type two diabetes.

Authors:  R Maldonado-Ruiz; L Montalvo-Martínez; L Fuentes-Mera; A Camacho
Journal:  Nutr Diabetes       Date:  2017-03-20       Impact factor: 5.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.